BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 38861187)

  • 1. MARCH5 promotes hepatocellular carcinoma progression by inducing p53 ubiquitination degradation.
    Cai X; Gao J; Yan Z; Zhang H; Guo D; Zhang S
    J Cancer Res Clin Oncol; 2024 Jun; 150(6):303. PubMed ID: 38861187
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aerobic glycolysis and tumor progression of hepatocellular carcinoma are mediated by ubiquitin of P53 K48-linked regulated by TRIM37.
    Ge Y; Zhao R; Li B; Xiao B; Zhou L; Zuo S
    Exp Cell Res; 2022 Dec; 421(2):113377. PubMed ID: 36252649
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tripartite motif 8 promotes the progression of hepatocellular carcinoma via mediating ubiquitination of HNF1α.
    Peng Y; Qian H; Xu WP; Xiao MC; Ding CH; Liu F; Hong HY; Liu SQ; Zhang X; Xie WF
    Cell Death Dis; 2024 Jun; 15(6):416. PubMed ID: 38879600
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PSMD9 promotes the malignant progression of hepatocellular carcinoma by interacting with c-Cbl to activate EGFR signaling and recycling.
    Su Y; Meng L; Ge C; Liu Y; Zhang C; Yang Y; Tian W; Tian H
    J Exp Clin Cancer Res; 2024 May; 43(1):142. PubMed ID: 38745188
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TRIM52 up-regulation in hepatocellular carcinoma cells promotes proliferation, migration and invasion through the ubiquitination of PPM1A.
    Zhang Y; Tao R; Wu SS; Xu CC; Wang JL; Chen J; Yu YS; Tang ZH; Chen XH; Zang GQ
    J Exp Clin Cancer Res; 2018 Jun; 37(1):116. PubMed ID: 29898761
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Upregulated TRIM11 Exerts its Oncogenic Effects in Hepatocellular Carcinoma Through Inhibition of P53.
    Liu J; Rao J; Lou X; Zhai J; Ni Z; Wang X
    Cell Physiol Biochem; 2017; 44(1):255-266. PubMed ID: 29190611
    [TBL] [Abstract][Full Text] [Related]  

  • 7. E3 ligase ZFP91 inhibits Hepatocellular Carcinoma Metabolism Reprogramming by regulating PKM splicing.
    Chen D; Wang Y; Lu R; Jiang X; Chen X; Meng N; Chen M; Xie S; Yan GR
    Theranostics; 2020; 10(19):8558-8572. PubMed ID: 32754263
    [No Abstract]   [Full Text] [Related]  

  • 8. Ubiquitin-specific protease 2a promotes hepatocellular carcinoma progression via deubiquitination and stabilization of RAB1A.
    Xiong B; Huang J; Liu Y; Zou M; Zhao Z; Gong J; Wu X; Qiu C
    Cell Oncol (Dordr); 2021 Apr; 44(2):329-343. PubMed ID: 33074477
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TRIM65 triggers β-catenin signaling via ubiquitylation of Axin1 to promote hepatocellular carcinoma.
    Yang YF; Zhang MF; Tian QH; Zhang CZ
    J Cell Sci; 2017 Sep; 130(18):3108-3115. PubMed ID: 28754688
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TRIM31 is upregulated in hepatocellular carcinoma and promotes disease progression by inducing ubiquitination of TSC1-TSC2 complex.
    Guo P; Ma X; Zhao W; Huai W; Li T; Qiu Y; Zhang Y; Han L
    Oncogene; 2018 Jan; 37(4):478-488. PubMed ID: 28967907
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fbxw7 is an independent prognostic marker and induces apoptosis and growth arrest by regulating YAP abundance in hepatocellular carcinoma.
    Tu K; Yang W; Li C; Zheng X; Lu Z; Guo C; Yao Y; Liu Q
    Mol Cancer; 2014 May; 13():110. PubMed ID: 24884509
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel long non-coding RNA RP11-286H15.1 represses hepatocellular carcinoma progression by promoting ubiquitination of PABPC4.
    Jiang X; Wang G; Liu Y; Mei C; Yao Y; Wu X; Chen X; Ma W; Li K; Zhang Z; Yuan Y
    Cancer Lett; 2021 Feb; 499():109-121. PubMed ID: 33259899
    [TBL] [Abstract][Full Text] [Related]  

  • 13. UCHL5 promotes hepatocellular carcinoma progression by promoting glycolysis through activating Wnt/β-catenin pathway.
    Wan B; Cheng M; He T; Zhang L
    BMC Cancer; 2024 May; 24(1):618. PubMed ID: 38773433
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FBXO22 promotes the development of hepatocellular carcinoma by regulating the ubiquitination and degradation of p21.
    Zhang L; Chen J; Ning D; Liu Q; Wang C; Zhang Z; Chu L; Yu C; Liang HF; Zhang B; Chen X
    J Exp Clin Cancer Res; 2019 Feb; 38(1):101. PubMed ID: 30808376
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Deubiquitinase USP39 and E3 ligase TRIM26 balance the level of ZEB1 ubiquitination and thereby determine the progression of hepatocellular carcinoma.
    Li X; Yuan J; Song C; Lei Y; Xu J; Zhang G; Wang W; Song G
    Cell Death Differ; 2021 Aug; 28(8):2315-2332. PubMed ID: 33649471
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Downregulation of PRAME Suppresses Proliferation and Promotes Apoptosis in Hepatocellular Carcinoma Through the Activation of P53 Mediated Pathway.
    Zhu H; Wang J; Yin J; Lu B; Yang Q; Wan Y; Jia C
    Cell Physiol Biochem; 2018; 45(3):1121-1135. PubMed ID: 29439259
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The mu-opioid receptor is a molecular marker for poor prognosis in hepatocellular carcinoma and represents a potential therapeutic target.
    Chen DT; Pan JH; Chen YH; Xing W; Yan Y; Yuan YF; Zeng WA
    Br J Anaesth; 2019 Jun; 122(6):e157-e167. PubMed ID: 30915986
    [TBL] [Abstract][Full Text] [Related]  

  • 18. UBE2T promotes hepatocellular carcinoma cell growth via ubiquitination of p53.
    Liu LP; Yang M; Peng QZ; Li MY; Zhang YS; Guo YH; Chen Y; Bao SY
    Biochem Biophys Res Commun; 2017 Nov; 493(1):20-27. PubMed ID: 28935368
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased mitochondrial fission promotes autophagy and hepatocellular carcinoma cell survival through the ROS-modulated coordinated regulation of the NFKB and TP53 pathways.
    Huang Q; Zhan L; Cao H; Li J; Lyu Y; Guo X; Zhang J; Ji L; Ren T; An J; Liu B; Nie Y; Xing J
    Autophagy; 2016 Jun; 12(6):999-1014. PubMed ID: 27124102
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overexpression of WWP1 promotes tumorigenesis and predicts unfavorable prognosis in patients with hepatocellular carcinoma.
    Zhang XF; Chao J; Pan QZ; Pan K; Weng DS; Wang QJ; Zhao JJ; He J; Liu Q; Jiang SS; Chen CL; Zhang HX; Xia JC
    Oncotarget; 2015 Dec; 6(38):40920-33. PubMed ID: 26506518
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.